BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/19/2017 11:16:00 AM | Browse: 1333 | Download: 2313
 |
Received |
|
2016-09-15 09:32 |
 |
Peer-Review Started |
|
2016-09-15 22:01 |
 |
To Make the First Decision |
|
2016-10-10 13:27 |
 |
Return for Revision |
|
2016-10-13 17:26 |
 |
Revised |
|
2016-10-26 18:41 |
 |
Second Decision |
|
2016-11-11 14:39 |
 |
Accepted by Journal Editor-in-Chief |
|
2016-11-11 23:49 |
 |
Accepted by Executive Editor-in-Chief |
|
2016-11-16 16:36 |
 |
Articles in Press |
|
2016-11-16 16:36 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2016-12-28 20:26 |
 |
Publish the Manuscript Online |
|
2017-01-19 11:16 |
ISSN |
1007-9327 (print) and 2219-2840 (online) |
Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
|
Copyright |
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
|
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Gastroenterology & Hepatology |
Manuscript Type |
Retrospective Study |
Article Title |
Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Kouichi Sakurai, Hiroko Suda, Yumi Ido, Takayuki Takeichi, Ayako Okuda, Kiwamu Hasuda and Masahiro Hattori |
Funding Agency and Grant Number |
|
Corresponding Author |
Kouichi Sakurai, MD, Hattori Clinic, Kumamoto, 2-12-35 Shin-machi, Chuo-ku, Kumamoto 860-0004, Japan. sakuraiko@jcom.zaq.ne.jp
|
Key Words |
Helicobacter pylori; Eradication treatment; Vonoprazan; Proton pump inhibitors; Adverse event; Smoking |
Core Tip |
Because the Helicobacter pylori (H. pylori) eradication rate of conventional proton pump inhibi-tor (PPI)-based treatment has decreased because clarithromycin-resistant strains have appeared in recent years, a new treatment strategy is required. Vonoprazan is a novel potassium -competitive acid blocker that has strong, long-lasting effects, but few studies have investigated its efficacy against H. pylori. We compared vonoprazan-based therapy and PPI-based therapy as first-line and second-line treatments. Vonoprazan-based therapy was superior to PPI-based therapy, particularly for smokers, but adverse events (AEs) due to vonoprazan occurred more frequently. Vonoprazan-based therapy is a potentially efficacious treatment, but it should be used with caution due to possible AEs.
|
Publish Date |
2017-01-19 11:16 |
Citation |
Sakurai K, Suda H, Ido Y, Takeichi T, Okuda A, Hasuda K, Hattori M. Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy. World J Gastroenterol 2017; 23(4): 668-675 |
URL |
http://www.wjgnet.com/1007-9327/full/v23/i4/668.htm |
DOI |
http://dx.doi.org/10.3748/wjg.v23.i4.668 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345